Marine-derived angiogenesis inhibitors for cancer therapy

Wang, Ying-Qing; Miao, Ze-Hong

doi:10.3390/md11030903

Cited by 72Angiogenesis and VEGF in CancerBioactive natural compoundsMarine Sponges and Natural Products

Marine-derived angiogenesis inhibitors for cancer therapy

Open access

Wang, Ying-Qing, Miao, Ze-Hong·2013·Marine Drugs

DOI 10.3390/md11030903PMC PMC3705379

Open this paper in CoChat — free account

Abstract

Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents display interesting characteristics, including diverse sources, unique chemical structures, special modes of action, and distinct activity and toxicity profiles. This review will first provide an overview of the current marine-derived angiogenesis inhibitors based on their primary targets and/or mechanisms of action. Then, the marine-derived antiangiogenic protein kinase inhibitors will be focused on. And finally, the clinical trials of the marine-derived antiangiogenic agents will be discussed, with special emphasis on their application potentials, problems and possible coping strategies in their future development as anticancer drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/md11030903

Cites

186 of 186 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin's lymphoma, renal cancer and colorectal cancer.
“The bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin’s lymphoma, renal cancer and colorectal cancer [58,59,60].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [59]
Section 4.1 reports phase I and II bryostatin-1 trials involving all four named cancers, and the References list phase II studies for each, including colorectal cancer (ref. 132). But the paper says more than 80 phase I and II trials had been conducted since 1993; it does not support the claim that bryostatin-1 had recently entered phase II trials. (LLM, conf=0.88)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Angiogenesis
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209 · see citing works
Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus <i>Salinospora</i>
Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., & Fenical, W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390115 · Cited by 1,057 · see citing works
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
Cumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D'Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwm014 · Cited by 1,026 · see citing works
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · see citing works
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W. R., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C. M., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 669 · see citing works
Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities
Koyanagi, S., Tanigawa, N., Nakagawa, H., Soeda, S., & Shimeno, H. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01478-8 · Cited by 479 · see citing works
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404 · see citing works
Targeting the protein kinase C family: are we there yet?
MacKay, H. J., & Twelves, C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2168 · Cited by 373 · see citing works
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 358 · see citing works
Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., & Davidson, B. S. (1999) · PubMed · Cited by 330 · see citing works
Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase
Piña, I. C., Gautschi, J. T., Wang, G.-Y.-S., Sanders, M. L., Schmitz, F. J., France, D. S., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S., Perez, L. B., et al. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo034248t · Cited by 314 · see citing works
Cortistatins A, B, C, and D, Anti-angiogenic Steroidal Alkaloids, from the Marine Sponge Corticium simplex
Aoki, S., Watanabe, Y., Sanagawa, M., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057404h · Cited by 293 · see citing works
Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589
Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B. C., Sanni, T. B., Atadja, P. W., & Пили, Р. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1132 · Cited by 267 · see citing works
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 266 · see citing works
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Younes, A., Sureda, A. M., Ben‐Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M. H., Johnston, P. B., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263 · see citing works
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent
Nicholson, B., Lloyd, G. K., Miller, B., et al. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000182745.01612.8a · Cited by 260 · see citing works
Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts.
Szállási, Z., Smith, C. B., Pettit, G. R., et al. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42143-0 · Cited by 241 · see citing works
Antivascular Actions of Microtubule-Binding Drugs
Schwartz, E. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2710 · Cited by 217 · see citing works
Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo
Xue, M., Ge, Y., Zhang, J., Wang, Q., Hou, L., Liu, Y., Sun, L., & Li, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043483 · Cited by 192 · see citing works
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3 · Cited by 187 · see citing works
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
Rapisarda, A., & Melillo, G. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 180 · see citing works
The chemistry and biology of the bryostatin antitumour macrolides
Hale, K. J., Hummersone, M., Manaviazar, S., et al. (2002) · Natural Product Reports · doi:10.1039/b009211h · Cited by 178 · see citing works
Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature.
Sills, A. K., Williams, J. I., Tyler, B., Epstein, D. S., Sipos, E. P., Davis, J. D., McLane, M. P., Pitchford, S. C., Cheshire, K., Gannon, F. H., et al. (1998) · PubMed · Cited by 168 · see citing works
Matrix metalloproteinases in vascular physiology and disease
Siefert, S. A., & Sarkar, R. (2012) · Vascular · doi:10.1258/vasc.2011.201202 · Cited by 157 · see citing works
PE, a new sulfated saponin from sea cucumber, Exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo
Tian, F., Zhang, X., Tong, Y., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.1917 · Cited by 154 · see citing works
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Millward, M., Price, T. J., Townsend, A. R., Sweeney, C. J., Spencer, A. G., Sukumaran, S., Longenecker, A. M., Lee, L., Lay, A., Sharma, G. D., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9766-6 · Cited by 151 · see citing works
Ageladine A: An Antiangiogenic Matrixmetalloproteinase Inhibitor from the Marine Sponge Agelas nakamurai
Fujita, M., Nakao, Y., Matsunaga, S., Seiki, M., Itoh, Y., Yamashita, J. K., van Soest, R. W. M., & Fusetani, N. (2003) · Journal of the American Chemical Society · doi:10.1021/ja038025w · Cited by 146 · see citing works
Proteomics-based Target Identification
Towbin, H., Bair, K. W., DeCaprio, J. A., Eck, M. J., Kim, S., Kinder, F. R. J., Morollo, A. A., Mueller, D. R., Schindler, P. A., Song, H. K., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309039200 · Cited by 146 · see citing works
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.
Logothetis, C. J., Wu, K. K., Finn, L. D., et al. (2001) · PubMed · Cited by 141 · see citing works
Low-Molecular-Weight Fucoidan Promotes Therapeutic Revascularization in a Rat Model of Critical Hindlimb Ischemia
Luyt, C., Meddahi‐Pellé, A., Ho‐Tin‐Noé, B., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046144 · Cited by 139 · see citing works
Low Molecular Weight Fucoidan Increases VEGF165-induced Endothelial Cell Migration by Enhancing VEGF165 Binding to VEGFR-2 and NRP1
Lake, A. C., Vassy, R., Benedetto, M. D., Lavigne, D., Visage, C. L., Perret, G. Y., & Letourneur, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600686200 · Cited by 129 · see citing works
Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping
Bennett, M. J., Barakat, K., Huzil, J. T., Tuszyński, J. A., & Schriemer, D. C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.019 · Cited by 128 · see citing works
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Duvic, M., Dummer, R., Becker, J. C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.017 · Cited by 127 · see citing works
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB–regulated gene products
Ahn, K. S., Sethi, G., Chao, T., Neuteboom, S., Chaturvedi, M. M., Palladino, M. A., Younes, A., & Aggarwal, B. B. (2007) · Blood · doi:10.1182/blood-2007-04-084996 · Cited by 122 · see citing works
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
Falardeau, P., Champagne, P., Poyet, P., Hariton, C., & Dupont, �. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90035-1 · Cited by 122 · see citing works
The Spongistatins, Potently Cytotoxic Inhibitors of Tubulin Polymerization, Bind in a Distinct Region of the Vinca Domain
Bai, R., Taylor, G. F., Cichacz, Z. A., et al. (1995) · Biochemistry · doi:10.1021/bi00030a009 · Cited by 119 · see citing works
Two New Xanthone Derivatives from the Algicolous Marine Fungus Wardomyces anomalus
Abdel‐Lateff, A., Klemke, C., König, G. M., & Wright, A. D. (2003) · Journal of Natural Products · doi:10.1021/np020518b · Cited by 119 · see citing works
The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8
Wrasidlo, W., Mielgo, A., Torres, V. A., Barbero, S., Stoletov, K. V., Suyama, T. L., Klemke, R. L., Gerwick, W. H., Carson, D. A., & Stupack, D. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712198105 · Cited by 118 · see citing works
Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szállási, Z., Denning, M. F., Smith, C. B., et al. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09823-2 · Cited by 118 · see citing works
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Wolf, J. L., Siegel, D. S. D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B., Matous, J., Vij, R., Magalhaes-Silverman, M. D., Abonour, R., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.661175 · Cited by 116 · see citing works
Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells
Liu, F., Wang, J., Chang, A. K., Liu, B., Yang, L., Li, Q., Wang, P., & Zou, X. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.03.015 · Cited by 115 · see citing works
Philinopside a, a novel marine‐derived compound possessing dual anti‐angiogenic and anti‐tumor effects
Tong, Y., Zhang, X., Tian, F., Yi, Y., Xu, Q.-Z., Li, L., Tong, L., Lin, L., & Ding, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20804 · Cited by 109 · see citing works
Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells
Matsubara, K., Xue, C.-H., Zhao, X., Mori, M., Sugawara, T., & Hirata, T. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.15.4.695 · Cited by 109 · see citing works
Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action
Soeda, S., Kozako, T., Iwata, K., & Shimeno, H. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00052-5 · Cited by 108 · see citing works
Cortistatin A is a High‐Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11
Cee, V. J., Chen, D. Y. ‐., Lee, M. R., & Nicolaou, K. C. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904778 · Cited by 106 · see citing works
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
Mita, M. M., Spear, M. A., Yee, L., Mita, A. C., Heath, E. I., Papadopoulos, K. P., Federico, K. C., Reich, S. D., Romero, O., Malburg, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1096 · Cited by 105 · see citing works
Role of the Cytoskeleton in Formation and Maintenance of Angiogenic Sprouts
Bayless, K. J., & Johnson, G. A. (2011) · Journal of Vascular Research · doi:10.1159/000324751 · Cited by 104 · see citing works
Role of Aminopeptidase in Angiogenesis
Sato, Y. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.772 · Cited by 104 · see citing works
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells
Ahn, M. Y., Jung, J. H., Na, Y. J., & Kim, H. S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.098 · Cited by 102 · see citing works
Azumamides A–E: Histone Deacetylase Inhibitory Cyclic Tetrapeptides from the Marine Sponge Mycale izuensis
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 102 · see citing works
Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum
Dias, P. F., Siqueira, J. M., Vendruscolo, L. F., Neiva, T. D. J. C., Gagliardi, A. R. D. T., Maraschin, M., & Ribeiro‐do‐Valle, R. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0995-7 · Cited by 99 · see citing works
Structure–activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids
Aoki, S., Watanabe, Y., Tanabe, D., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.017 · Cited by 98 · see citing works
Oligomannurarate Sulfate, a Novel Heparanase Inhibitor Simultaneously Targeting Basic Fibroblast Growth Factor, Combats Tumor Angiogenesis and Metastasis
Zhao, H., Liu, H., Chen, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1382 · Cited by 98 · see citing works
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian, M. L., Mohammad, R. M., Shurafa, M. S., Hulburd, K., Pemberton, P., Rodriguez, D. H., Spadoni, V., Eilender, D. S., Murgo, A. J., Wall, N. R., et al. (2000) · PubMed · Cited by 97 · see citing works
New Proteasome Inhibitors in Myeloma
Lawasut, P., Chauhan, D., Laubach, J. P., et al. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0141-2 · Cited by 93 · see citing works
Progress in the clinical development of new marine-derived anticancer compounds
Jimeno, J. M., Lopez-Martin, J. A., Ruiz‐Casado, A., et al. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00003 · Cited by 89 · see citing works
Antiangiogenic activity of aplidine, a new agent of marine origin
Taraboletti, G., Poli, M., Dossi, R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601864 · Cited by 89 · see citing works
Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Shuttleworth, S. J., Bailey, S. G., & Townsend, P. A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011430 · Cited by 88 · see citing works
A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
Hainsworth, J. D., Infante, J. R., Spigel, D. R., Arrowsmith, E. R., Boccia, R. V., & Burris, H. A. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.590568 · Cited by 88 · see citing works
Total Synthesis of Ageladine A, an Angiogenesis Inhibitor from the Marine Sponge Agelas nakamurai
Meketa, M. L., & Weinreb, S. M. (2006) · Organic Letters · doi:10.1021/ol0602304 · Cited by 85 · see citing works
The clinical development of the bryostatins
Clamp, A. R., & Jayson, G. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200208000-00001 · Cited by 83 · see citing works
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82 · see citing works
Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue
Dupont, É., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pépin, M.-C., Wang, T., & Alaoui‐Jamali, M. A. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1014546909573 · Cited by 81 · see citing works
Low Molecular Weight Fucoidan and Heparin Enhance the Basic Fibroblast Growth Factor-Induced Tube Formation of Endothelial Cells through Heparan Sulfate-Dependent α6 Overexpression
Chabut, D., Fischer, A., Colliec‐Jouault, S., Laurendeau, I., Matou, S., Bonniec, B. L., & Helley, D. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.696 · Cited by 81 · see citing works
Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro
Shim, J. S., Lee, H., Shin, J., & Kwon, H. J. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.036 · Cited by 78 · see citing works
Cytochalasin E, an Epoxide ContainingAspergillus-Derived Fungal Metabolite, Inhibits Angiogenesis and Tumor Growth
Udagawa, T., Yuan, J., Panigrahy, D., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39088-3 · Cited by 77 · see citing works
TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death
Otani, M., Natsume, T., Watanabe, J., et al. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01022.x · Cited by 75 · see citing works
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
Millward, M., Mainwaring, P. N., Mita, A. C., Federico, K. C., Lloyd, G. K., Reddinger, N., Nawrocki, S. T., Mita, M. M., & Spear, M. A. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9642-4 · Cited by 74 · see citing works
Arthrinins A–D: Novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.
Ebada, S. S., Schulz, B., Wray, V., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.013 · Cited by 73 · see citing works
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
Mateos, M., Cibeira, M. T., Richardson, P. G. G., Prósper, F., Oriol, A., de la Rubia, J., Lahuerta, J. J., García‐Sánz, R., Extremera, S., Szyldergemajn, S. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0469 · Cited by 73 · see citing works
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase
Kim, D. H., Shin, J., & Kwon, H. J. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.6 · Cited by 72 · see citing works
Inhibition of tumor cell invasion and angiogenesis by motuporamines.
Roskelley, C. D., Williams, D. E. J., McHardy, L. M., et al. (2001) · PubMed · Cited by 71 · see citing works
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial
Lu, C. S., Lee, J. J., Komaki, R. U., Herbst, R. S., Feng, L., Evans, W. K., Choy, H., Desjardins, P., Esparaz, B. T., Truong, M. T., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq179 · Cited by 71 · see citing works
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
Blackhall, F. H., Ranson, M., Radford, J. A., Hancock, B. W., Soukop, M., McGown, A. T., Robbins, A. K., & Halbert, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1624 · Cited by 68 · see citing works
Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
Abraham, I., Sayed, K. A. E., Chen, Z., & Guo, H. (2012) · Marine Drugs · doi:10.3390/md10102312 · Cited by 68 · see citing works
The Development of MetAP-2 Inhibitors in Cancer Treatment
Yin, S.-Q., Wang, J.-J., Zhang, C.-M., & Liu, Z.-P. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320709 · Cited by 68 · see citing works
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
Ajani, J. A., Jiang, Y., Faust, J., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-6452-1 · Cited by 66 · see citing works
Study of puupehenone and related compounds as inhibitors of angiogenesis
Castro, M. E., González‐Iriarte, M., Barrero, A. F., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20068 · Cited by 66 · see citing works
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau, R., Gingras, D. J., Kruger, E. A., et al. (2002) · PubMed · Cited by 66 · see citing works
Synthesis and Antitumor Activity of Ester-Modified Analogues of Bengamide B
Kinder, F. R. J., Versace, R. W., Bair, K. W., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010188c · Cited by 65 · see citing works
Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973
Shin, H. J., Kim, T. S., Lee, H., Park, J. Y., Choi, I.-K., & Kwon, H. J. (2008) · Phytochemistry · doi:10.1016/j.phytochem.2008.05.020 · Cited by 65 · see citing works
Squalamine Lactate Reduces Choroidal Neovascularization in a Laser-Injury Model in the Rat
Ciulla, T. A., Criswell, M. H., Danis, R. P., et al. (2003) · Retina · doi:10.1097/00006982-200312000-00011 · Cited by 64 · see citing works
Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.
Gingras, D., Renaud, A., Mousseau, N., Beaulieu, É., Kachra, Z., & Béliveau, R. (2001) · PubMed · Cited by 63 · see citing works
Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes.
Kazanietz, M. G., Lewin, N. E., Gao, F., et al. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09694-4 · Cited by 63 · see citing works
Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941
Escudier, B. J., Choueiri, T. K., Oudard, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.07.035 · Cited by 63 · see citing works
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Ribrag, V., Caballero, D., Fermé, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.069757 · Cited by 61 · see citing works
The Microtubule Binding Drug Laulimalide Inhibits Vascular Endothelial Growth Factor-Induced Human Endothelial Cell Migration and Is Synergistic when Combined with Docetaxel (Taxotere)
Lu, H., Murtagh, J., & Schwartz, E. L. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019075 · Cited by 61 · see citing works
Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant
Barr, P. M., Lazarus, H. M., Cooper, B., et al. (2009) · American Journal of Hematology · doi:10.1002/ajh.21449 · Cited by 60 · see citing works
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
Riely, G. J., Gadgeel, S. M., Rothman, I., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.10.002 · Cited by 58 · see citing works
Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with Tubulin
Natsume, T., Watanabe, J., Tamaoki, S., et al. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01007.x · Cited by 58 · see citing works
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy
PATEL, S. R., Keohan, M. L., Saif, M. W., et al. (2006) · Cancer · doi:10.1002/cncr.22334 · Cited by 57 · see citing works
Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib
Mitsiades, C. S., Hideshima, T., Chauhan, D., McMillin, D. W., Klippel, S., Laubach, J. P., Munshi, N. C., Anderson, K. C., & Richardson, P. G. G. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.003 · Cited by 57 · see citing works
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.
Boivin, D., Gendron, S. P., Beaulieu, É., Gingras, D., & Béliveau, R. (2002) · PubMed · Cited by 57 · see citing works
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
Tourneau, C. L., Raymond, É., & Faivre, S. J. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782360555 · Cited by 56 · see citing works
Control of HIF-1α Expression by eIF2α Phosphorylation–Mediated Translational Repression
Zhu, K., Chan, W., Heymach, J., Wilkinson, M., & McConkey, D. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4103 · Cited by 55 · see citing works
Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells
Aoki, S., Cho, S.-H., Ono, M., et al. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00005 · Cited by 54 · see citing works
A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis
Dias, P. F., Siqueira, J. M., Maraschin, M., Ferreira, A. G., Gagliardi, A. R. D. T., & Ribeiro‐do‐Valle, R. M. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.004 · Cited by 54 · see citing works
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes
Straight, A. M., Oakley, K., Moores, R., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0014-7 · Cited by 53 · see citing works
Concise Total Synthesis of the Marine Natural Product Ageladine A
Shengule, S. R., & Karuso, P. (2006) · Organic Letters · doi:10.1021/ol061584y · Cited by 53 · see citing works
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Wang, H., Cao, Q., & Dudek, A. Z. (2012) · PubMed · Cited by 53 · see citing works
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer
Dumez, H., Gall, H., Capdeville, R., Dutreix, C., van Oosterom, A. T., & Giaccone, G. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328010ef5b · Cited by 52 · see citing works
FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
Shafiq, M. I., Steinbrecher, T. B., & Schmid, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042612 · Cited by 51 · see citing works
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
Ku, G. Y., Ilson, D. H., Schwartz, L. H., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0677-y · Cited by 50 · see citing works
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Hao, D., Hammond, L. A., Eckhardt, S., et al. (2003) · PubMed · Cited by 50 · see citing works
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst, R. S., Hammond, L. A., Carbone, D. P., et al. (2003) · PubMed · Cited by 50 · see citing works
Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo
Lin, J., Yan, X., & Chen, H. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0282-x · Cited by 49 · see citing works
Application of a 6π-1-Azatriene Electrocyclization Strategy to the Total Synthesis of the Marine Sponge Metabolite Ageladine A and Biological Evaluation of Synthetic Analogues
Meketa, M. L., Weinreb, S. M., Nakao, Y., et al. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo0707232 · Cited by 49 · see citing works
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
Madhusudan, S., Protheroe, A. S., PROPPER, D. J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601321 · Cited by 48 · see citing works
Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors
Hinterding, K., Knebel, A., Herrlich, P., & Waldmann, H. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00070-4 · Cited by 48 · see citing works
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia
Ghobrial, I. M., Campigotto, F., Murphy, T. J., et al. (2013) · Blood · doi:10.1182/blood-2012-06-439307 · Cited by 47 · see citing works
Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent
Watanabe, J., Natsume, T., Fujio, N., Miyasaka, K., & Kobayashi, M. (2000) · APOPTOSIS · doi:10.1023/a:1009687609330 · Cited by 45 · see citing works
Antiangiogenic Metabolites from a Marine-Derived Fungus, Hypocrea vinosa
Ohkawa, Y., Miki, K., Suzuki, T., et al. (2010) · Journal of Natural Products · doi:10.1021/np900698p · Cited by 45 · see citing works
Novel isomarabarican triterpenes, exhibiting selective anti-proliferative activity against vascular endothelial cells, from marine sponge Rhabdastrella globostellata
Aoki, S., Sanagawa, M., Watanabe, Y., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.04.070 · Cited by 45 · see citing works
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
Strickler, J. H., Starodub, A., Jia, J., Meadows, K. L., Nixon, A. B., Dellinger, A. E., Morse, M. A., Uronis, H. E., Marcom, P. K., Zafar, S. Y., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1911-1 · Cited by 44 · see citing works
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
Offidani, M., Polloni, C., Cavallo, F., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.664844 · Cited by 44 · see citing works
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study
Morgan, R. J., Leong, L., Chow, W. A., Gandara, D. R., Frankel, P. H., García, A. A., Lenz, H., & Doroshow, J. H. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9557-5 · Cited by 44 · see citing works
Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma
Varterasian, M. L., Pemberton, P., Hulburd, K., et al. (2001) · Investigational New Drugs · doi:10.1023/a:1010676719178 · Cited by 42 · see citing works
The Tumor Invasion Inhibitor Dihydromotuporamine C Activates RHO, Remodels Stress Fibers and Focal Adhesions, and Stimulates Sodium–Proton Exchange
McHardy, L. M., Sinotte, R., Troussard, A. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2733 · Cited by 42 · see citing works
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
Winegarden, J. A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00447-6 · Cited by 42 · see citing works
Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
Lam, A. P., Sparano, J. A., Vinciguerra, V. P., Ocean, A. J., Christos, P. J., Höchster, H. S., Camacho, F., Goel, S., Mani, S., & Kaubisch, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181a31920 · Cited by 41 · see citing works
Phase II evaluation of bryostatin-1 in metastatic melanoma
Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40 · see citing works
Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Mauriz, J. L., Martín‐Renedo, J., Palomo, A. G., Tuñón, M. J., & González‐Gallego, J. (2010) · Current Drug Targets · doi:10.2174/1389450111009011439 · Cited by 40 · see citing works
Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma
Schöffski, P., Guillem, V., García, M., et al. (2009) · Marine Drugs · doi:10.3390/md7010057 · Cited by 39 · see citing works
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
Clamp, A. R., Blackhall, F. H., Vasey, P. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601285 · Cited by 39 · see citing works
Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model
Yan, X., Chen, H., Lü, X., et al. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.04.018 · Cited by 38 · see citing works
Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity
Zheng, Y. L., LU, X. L., Lin, J., Chen, H. M., Yan, X. J., Wang, F., & Xu, W. F. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.04.046 · Cited by 38 · see citing works
The Antiangiogenic Compound Aeroplysinin-1 Induces Apoptosis in Endothelial Cells by Activating the Mitochondrial Pathway
Martı́nez-Poveda, B., Rodrı́guez-Nieto, S., García‐Caballero, M., Medina, M. Á., & Quesada, A. R. (2012) · Marine Drugs · doi:10.3390/md10092033 · Cited by 38 · see citing works
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study
Nezhat, F. R., Wadler, S., Muggia, F. M., et al. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.021 · Cited by 37 · see citing works
Investigation of the marine compound spongistatin 1 links the inhibition of PKCα translocation to nonmitotic effects of tubulin antagonism in angiogenesis
Rothmeier, A. S., Ischenko, I., Joore, J., et al. (2008) · The FASEB Journal · doi:10.1096/fj.08-117127 · Cited by 36 · see citing works
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
Caers, J., Menu, E., Raeve, H. D., LePage, D., Valckenborgh, E. V., Camp, B. V., Álvarez, E., & Vanderkerken, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604388 · Cited by 36 · see citing works
Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia
Hraiech, S., Brégeon, F., Brunel, J. M., Rolain, J., Lépidi, H., Andrieu, V., Raoult, D., Papazian, L., & Roch, A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks230 · Cited by 36 · see citing works
Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs
Ando, N., & Terashima, S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.005 · Cited by 35 · see citing works
Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both α- and β-tubulin
Yamazaki, Y., Sumikura, M., Hidaka, K., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.037 · Cited by 35 · see citing works
A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study
Geoerger, B., Estlin, E. J., Aerts, I., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.036 · Cited by 33 · see citing works
Pyripyropenes, Fungal Sesquiterpenes Conjugated with .ALPHA.-Pyrone and Pyridine Moieties, Exhibits Anti-angiogenic Activity against Human Umbilical Vein Endothelial Cells
Hayashi, A., Arai, M., Fujita, M., et al. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1261 · Cited by 33 · see citing works
A One-Pot Synthesis and Biological Activity of Ageladine A and Analogues
Shengule, S. R., Loa-Kum-Cheung, W. L., Parish, C. R., Blairvacq, M., Meijer, L., Nakao, Y., & Karuso, P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200039m · Cited by 33 · see citing works
Actin Disruption Inhibits Bombesin Stimulation of Focal Adhesion Kinase (pp125FAK) in Prostate Carcinoma
Duncan, M. D., Harmon, J. W., & Duncan, K. L. K. (1996) · Journal of Surgical Research · doi:10.1006/jsre.1996.0276 · Cited by 33 · see citing works
Streptochlorin, a marine natural product, inhibits NF-kappaB activation and suppresses angiogenesis in vitro.
Choi, I.-K., Shin, H. J., Lee, H. S., & Kwon, H. J. (2007) · PubMed · Cited by 33 · see citing works
The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo
Ma, J., Xin, X., Meng, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003774 · Cited by 32 · see citing works
Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer
Brockstein, B., Samuels, B. L., Humerickhouse, R. A., Arrieta, R. L., Fishkin, P. A. S., Wade, J., Sosman, J. A., & Vokes, E. E. (2001) · Investigational New Drugs · doi:10.1023/a:1010628903248 · Cited by 31 · see citing works
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
Eisen, T. G., Thomas, J., Miller, W. H., et al. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e32832bbde6 · Cited by 31 · see citing works
Challenges to the development of bryostatin‐type anticancer drugs based on the activation mechanism of protein kinase Cδ
Irie, K., Yanagita, R. C., & Nakagawa, Y. (2010) · Medicinal Research Reviews · doi:10.1002/med.20220 · Cited by 31 · see citing works
Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
Sharma, M. R., Karrison, T. G., Jin, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1815 · Cited by 30 · see citing works
Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Mottet, D., & CASTRONOVO, V. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793358014 · Cited by 30 · see citing works
Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas, N. B., Smith, M. R., Lewis, N. L., et al. (2003) · PubMed · Cited by 30 · see citing works
Structural Analysis of Bengamide Derivatives as Inhibitors of Methionine Aminopeptidases
Xü, W., Lu, J.-P., & Ye, Q.-Z. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008695 · Cited by 29 · see citing works
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome
Dimicoli, S., Jabbour, E. J., Borthakur, G. M., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22198 · Cited by 29 · see citing works
Antiangiogenic properties of a sulfated galactan isolated from a marine green alga, Codium cylindricum
Matsubara, K., Mori, M., Matsumoto, H., Hori, K., & Miyazawa, K. (2003) · Journal of Applied Phycology · doi:10.1023/a:1022958222915 · Cited by 28 · see citing works
Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration
Sallam, A. A., Ramasahayam, S., Meyer, S. A., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.057 · Cited by 28 · see citing works
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).
Richardson, P. G. G., Hofmeister, C. C., Jakubowiak, A. J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.431.431 · Cited by 28 · see citing works
Phase II Study of Plitidepsin 3-Hour Infusion Every 2 Weeks in Patients With Unresectable Advanced Medullary Thyroid Carcinoma
Baudin, É., Droz, J. P., Paz-Ares, L. G., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31819fdf5e · Cited by 27 · see citing works
Roles of P67/MetAP2 as a tumor suppressor
Datta, B. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.002 · Cited by 27 · see citing works
FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug Fumagillin (TNP‐470)
Chen, G. J., Weylie, B., Chen, H., et al. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21265 · Cited by 27 · see citing works
Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
Barboza, N. M., Medina, D. J., Budak-Alpdoǧan, T., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.2.18876 · Cited by 26 · see citing works
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
Peschel, C., Hartmann, J. T., Schmittel, A. H., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.10.019 · Cited by 26 · see citing works
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer
Eisen, T. G., Thatcher, N., Leyvraz, S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.017 · Cited by 25 · see citing works
Incorporated nematocysts in Aeolidiella stephanieae (Gastropoda, Opisthobranchia, Aeolidoidea) mature by acidification shown by the pH sensitive fluorescing alkaloid Ageladine A
Obermann, D., Bickmeyer, U., & Wägele, H. (2012) · Toxicon · doi:10.1016/j.toxicon.2012.08.003 · Cited by 25 · see citing works
Total Synthesis and Absolute Configuration of Laurenditerpenol: A Hypoxia Inducible Factor-1 Activation Inhibitor
Chittiboyina, A. G., Kumar, G. M., de Carvalho, P. B., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7011062 · Cited by 25 · see citing works
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)
Fortunati, N., Catalano, M. G., Marano, F., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0789-z · Cited by 24 · see citing works
A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo
Tang, X., Li, J., Xin, X., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.11.3278 · Cited by 24 · see citing works
A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Pfister, D. G., McCaffrey, J., Zahalsky, A. J., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1014449309165 · Cited by 23 · see citing works
Newly discovered angiogenesis inhibitors and their mechanisms of action
Miao, Z., Feng, J., & Ding, J. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.97 · Cited by 23 · see citing works
Self-citation
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells
Nakao, Y., Narazaki, G., Hoshino, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.053 · Cited by 23 · see citing works
The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity
Gingras, D. J., Labelle, D., Nyalendo, C., et al. (2003) · Investigational New Drugs · doi:10.1023/b:drug.0000006171.54078.3d · Cited by 22 · see citing works
The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
Rothmeier, A. S., Schneiders, U. M., Wiedmann, R. M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25241 · Cited by 22 · see citing works
A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study
Tozer, R. G., Burdette-Radoux, S., Berlanger, K., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1020694425356 · Cited by 20 · see citing works
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
Armstrong, D. K., Blessing, J. A., Rader, J. S., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1026255403046 · Cited by 20 · see citing works
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study
Armstrong, D. K., Blessing, J. A., Look, K. Y., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1025490818450 · Cited by 20 · see citing works
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
Jones, S. F., Infante, J. R., Thompson, D. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1931-x · Cited by 20 · see citing works
Cytochalasin E enhances the protein kinase C-dependent process of secretion
Cox, A. C. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(88)90454-8 · Cited by 18 · see citing works
First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052
Hamlin, P. A., Aghajanian, C. A., Younes, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3516 · Cited by 18 · see citing works
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Peterson, A., Harlin, H., Karrison, T., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-5935-4 · Cited by 17 · see citing works
The Alkaloid Ageladine A, Originally Isolated from Marine Sponges, Used for pH-Sensitive Imaging of Transparent Marine Animals
Bickmeyer, U. (2012) · Marine Drugs · doi:10.3390/md10010223 · Cited by 16 · see citing works
Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci)
Honda-Uezono, A., Kaida, A., Michi, Y., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.014 · Cited by 15 · see citing works
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
Soto-Matos, A., Szyldergemajn, S. A., Extremera, S., et al. (2011) · Marine Drugs · doi:10.3390/md9061007 · Cited by 15 · see citing works
Synthesis of Neolamellarin A, an Inhibitor of Hypoxia-Inducible Factor-1
Arafeh, K. M., & Ullah, N. (2009) · Natural Product Communications · doi:10.1177/1934578x0900400709 · Cited by 14 · see citing works
Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)
Hofmeister, C. C., Richardson, P. G. G., Zimmerman, T. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8505 · Cited by 13 · see citing works
Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization
Bennett, M. J., Chan, G. K. T., Rattner, J. B., & Schriemer, D. C. (2012) · Cell Cycle · doi:10.4161/cc.21411 · Cited by 11 · see citing works
Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.
Watanabe, J., Endo, Y., Shimada, N., et al. (2007) · PubMed · Cited by 11 · see citing works
Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma
Richardson, P. G. G., Hofmeister, C. C., Zimmerman, T. M., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2770.2770 · Cited by 11 · see citing works
Reversal of TNP-470-Induced Endothelial Cell Growth Arrest by Guanine and Guanine Nucleosides
Hines, J. F., Ju, R., Dutschman, G. E., Cheng, Y., & Crews, C. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169110 · Cited by 9 · see citing works
Depolymerization of Actin Filament by Cytochalasin E Induces Interleukin‐8 Production and Up‐Regulates CD54 in the HeLa Epithelial Cell Line
Ikewaki, N., Yamada, A., & Inoko, H. (2003) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2003.tb03435.x · Cited by 8 · see citing works
Squalamine and its derivatives as potential antitubercular compounds
Walker, B. T., & Houston, T. A. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.08.002 · Cited by 8 · see citing works
A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.
Advani, A. S., Copelan, E. A., Sobecks, R. M., et al. (2008) · Blood · doi:10.1182/blood.v112.11.955.955 · Cited by 2 · see citing works
Shark cartilage: has the popularisation of science failed?
Alifrangis, C., & Stebbing, J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70425-9 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Authors: Wang, Y.-Q., & Miao, Z.-H.
Affiliations: Chinese Academy of Sciences (CN)
Corresponding author: Miao, Ze-Hong
ORCID: Wang, Ying-Qing
Miao, Ze-Hong
Venue: Marine Drugs
Publisher: MDPI AG
Published: 2013-03-15
Volume: 11
Issue: 3
Pages: 903-933
ISSN: 1660-3397 (ISSN-L)
DOI: 10.3390/md11030903
PMC: PMC3705379
OpenAlex: W2013913223
Cited by: 72
References: 186
Citations by year: 2025: 4 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 10 · 2013: 4 · 2012: 1
FWCI: 3.88
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/3.0/ (vor)
Locations: Marine Drugs (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioactive natural compounds
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
Keywords: angiogenesis inhibitors, marine natural products, antiangiogenic activity, cancer therapy, protein kinase inhibitors, clinical trials, drug development
MeSH terms: Animals, Antineoplastic Agents, Humans, Neoplasms, Neovascularization, Pathologic, Drug Design, Angiogenesis Inhibitors, Protein Kinase Inhibitors, Aquatic Organisms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Marine-derived angiogenesis inhibitors for cancer therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks